ACLARIS THERAPEUTICS INC (ACRS)
Health Care · Clinical-stage biopharmaceutical (dermatology focus) · NASDAQ
Early-stage dermatology-focused biotech developing partnerships and seeking commercialization pathways for its pipeline of therapeutic candidates.
What ACLARIS THERAPEUTICS INC does
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drug candidates for dermatological and other therapeutic areas. The company generates minimal revenue through contract research and licensing arrangements while investing substantially in research and development efforts and seeking third-party partnerships to advance its product candidates toward clinical development and commercialization.
Themes: ["Clinical-stage biopharmaceutical development","Dermatology","Drug discovery and development"]
Fundamentals
- Price$5.71 as of 2026-07-09 close
- Market cap$808M as of 2026-07-10
- 1-year return+270.8% as of 2026-07-09 close
- Net margin-832.6% as of 2026-07-10
- Gross margin+9.7% as of 2026-07-10
- ROE-55.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-52.9% as of 2026-07-10
- Revenue CAGR (3y)-35.9% SEC XBRL
- Beta0.79 as of 2026-07-10
Key risks (from latest filing)
["Significant accumulated losses ($967.8 million deficit as of December 31, 2025) and no clear path to profitability; company expects to incur substantial losses over the next several years.","Heavy dependence on third-party partnerships for development and commercialization of product candidates; failure to secure or maintain partnerships could severely limit revenue potential and advancement of pipeline.","Capital constraints and need for substantial additional funding to pursue business objectives; inability to raise capital when needed could force curtailment of planned operations."]
Competitors & peers
- Retinoid X Receptor (RXR) agonist programs (various biotech players)
- Dermatological drug developers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.